These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 17325225)
41. FR209602 and related compounds, novel antifungal lipopeptides from coleophoma crateriformis no. 738. II. In vitro and in vivo antifungal activity. Kanasaki R; Abe F; Furukawa S; Yoshikawa K; Fujie A; Hino M; Hashimoto S; Hori Y J Antibiot (Tokyo); 2006 Mar; 59(3):145-8. PubMed ID: 16724454 [TBL] [Abstract][Full Text] [Related]
42. Differential in vitro activity of anidulafungin, caspofungin and micafungin against Candida parapsilosis isolates recovered from a burn unit. Ghannoum MA; Chen A; Buhari M; Chandra J; Mukherjee PK; Baxa D; Golembieski A; Vazquez JA Clin Microbiol Infect; 2009 Mar; 15(3):274-9. PubMed ID: 19210699 [TBL] [Abstract][Full Text] [Related]
43. Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009). Pfaller MA; Castanheira M; Messer SA; Moet GJ; Jones RN Diagn Microbiol Infect Dis; 2011 Jan; 69(1):45-50. PubMed ID: 21146713 [TBL] [Abstract][Full Text] [Related]
44. Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. Garcia-Effron G; Park S; Perlin DS Antimicrob Agents Chemother; 2009 Jan; 53(1):112-22. PubMed ID: 18955538 [TBL] [Abstract][Full Text] [Related]
45. The echinocandins. Cappelletty D; Eiselstein-McKitrick K Pharmacotherapy; 2007 Mar; 27(3):369-88. PubMed ID: 17316149 [TBL] [Abstract][Full Text] [Related]
46. Antifungal susceptibility of epigallocatechin 3-O-gallate (EGCg) on clinical isolates of pathogenic yeasts. Park BJ; Park JC; Taguchi H; Fukushima K; Hyon SH; Takatori K Biochem Biophys Res Commun; 2006 Aug; 347(2):401-5. PubMed ID: 16831406 [TBL] [Abstract][Full Text] [Related]
55. Reshaping Echinocandin Antifungal Drugs To Circumvent Glucan Synthase Point-Mutation-Mediated Resistance. Jospe-Kaufman M; Ben-Zeev E; Mottola A; Dukhovny A; Berman J; Carmeli S; Fridman M Angew Chem Int Ed Engl; 2024 Feb; 63(9):e202314728. PubMed ID: 38161189 [TBL] [Abstract][Full Text] [Related]
56. Characterization of echinocandin-resistant mutants of Candida albicans: genetic, biochemical, and virulence studies. Kurtz MB; Abruzzo G; Flattery A; Bartizal K; Marrinan JA; Li W; Milligan J; Nollstadt K; Douglas CM Infect Immun; 1996 Aug; 64(8):3244-51. PubMed ID: 8757860 [TBL] [Abstract][Full Text] [Related]
57. Genomics-driven discovery of a novel self-resistance mechanism in the echinocandin-producing fungus Pezicula radicicola. Yue Q; Li Y; Chen L; Zhang X; Liu X; An Z; Bills GF Environ Microbiol; 2018 Sep; 20(9):3154-3167. PubMed ID: 29528534 [TBL] [Abstract][Full Text] [Related]
58. Development and Validation of TaqMan Chemistry Probe-Based Rapid Assay for the Detection of Echinocandin-Resistance in Candida auris. Zhu Y; Hager KM; Manjari SR; Banavali NK; Chaturvedi V; Chaturvedi S J Clin Microbiol; 2023 Apr; 61(4):e0176722. PubMed ID: 36975998 [TBL] [Abstract][Full Text] [Related]
59. Caspofungin susceptibility in Aspergillus and non-Aspergillus molds: inhibition of glucan synthase and reduction of beta-D-1,3 glucan levels in culture. Kahn JN; Hsu MJ; Racine F; Giacobbe R; Motyl M Antimicrob Agents Chemother; 2006 Jun; 50(6):2214-6. PubMed ID: 16723587 [TBL] [Abstract][Full Text] [Related]
60. Photoaffinity analog of the semisynthetic echinocandin LY303366: identification of echinocandin targets in Candida albicans. Radding JA; Heidler SA; Turner WW Antimicrob Agents Chemother; 1998 May; 42(5):1187-94. PubMed ID: 9593148 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]